JKJakub Kralik

Jakub Kralik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jakub Kralik has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Sonja Kleinlogel

    Institute of Physiology and Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland

    5 shared publications
  • Michiel van Wyk

    Institute of Physiology and Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland

    2 shared publications
  • Nino Stocker

    Institute of Physiology and Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland

    2 shared publications
  • Amol Panhale

    Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland

    1 shared publication
  • Athéna Loye

    Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland

    1 shared publication
  • Audrey Vautheny

    Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland

    1 shared publication

Latest Publications

  • Open Access

    Proof-of-concept for the MRI-targeted delivery of naked antisense oligonucleotides to the murine striatum using focused ultrasound

    by Jakub Kralik, Lena Steinhauer, Hélène Vernin, Stephanie Schöppenthau, Sébastien Debilly, Thomas Bielser, Amol Panhale, Erich Koller, Basil Künnecke, Didier Wolter, et al.

    While the blood–brain barrier (BBB) is critical for maintaining the microenvironment of the central nervous system (CNS), it simultaneously acts as a bottleneck for successful delivery of the majority of therapeutics into the brain. Low intensity focused ultrasound (FUS) combined with systemically delivered microbubbles (MBs) has already been employed to transiently open the BBB in a spatially-restricted manner to enhance the delivery of therapeutics into the brain, including recombinant adeno-associated viruses (rAAVs), antibodies, nanoparticles, or small interfering RNAs. In this study we demonstrate the feasibility to enhance the delivery of systemically administered fluorescently-labeled antisense oligonucleotides (ASOs) into the murine striatum using magnetic resonance imaging (MRI) targeted FUS. We focused only on the acute biodistribution 30 min post-sonication and did not evaluate target knockdown or long-term safety. Immunohistological analysis revealed that majority of medium spiny neurons within the sampled sonicated striatal region were positive for the ASO. Absolute tissue quantification via LC-MS confirmed these findings, revealing a substantial increase in target tissue concentration. Taken together, these results suggest MRI-targeted FUS as a promising non-invasive technology to enhance the delivery of naked ASOs into deep structures of the brain.

  • Human myelinated brain organoids with integrated microglia as a model for myelin repair and remyelinating therapies

    by Simona Lange, Martin Ebeling, Athéna Loye, Florian Wanke, Juliane Siebourg-Polster, Tania J. J. Sudharshan, Franziska Völlmy, Jakub Kralik, Bérengère Vidal, Kerstin Hahn, et al.

    Oligodendrocytes, the myelinating cells of the central nervous system (CNS), are essential for the formation of myelin sheaths and pivotal for maintaining axonal integrity and conduction. Disruption of these cells and the myelin sheaths they produce is a hallmark of demyelinating conditions like multiple sclerosis or those resulting from certain drug side effects, leading to profound neurological impairments. In this study, we created a human brain organoid comprising neurons, astrocytes, and myelinating oligodendrocytes. By integrating induced pluripotent stem cell–derived microglia, we endowed these myelinated human brain organoids (MHBOs) with immune characteristics. MHBOs with microglia (MHBOs +MG) enabled the investigation of demyelination and remyelination—a process in which myelin sheaths are regenerated—in a human context. After toxin-induced demyelination, we observed a reduction in myelin followed by subsequent self-driven remyelination. Proteomic and transcriptomic analyses provided a molecular signature of demyelination and myelin recovery indicating a central role for microglia in the remyelination process. Furthermore, the application of the pro-remyelinating compounds clemastine, XAV939, and BQ3020 further enhanced remyelination in MHBOs +MG but was ineffective in the absence of microglia. Cross-validation of our findings in mouse cerebellar slice cultures confirmed that the pro-remyelinating compounds were effective ex vivo, suggesting the translational potential of our MHBOs +MG model.


  • Open Access

    Selective Block of Upregulated Kv1.3 Potassium Channels in ON-Bipolar Cells of the Blind Retina Enhances Optogenetically Restored Signaling

    by Giulia Schilardi, Jakub Kralik, Sonja Kleinlogel

    Loss of photoreceptors in retinal degenerative diseases also impacts the inner retina: bipolar cell dendrites retract, neurons rewire, and protein expression changes. ON-bipolar cells (OBCs) represent an attractive target for optogenetic vision restoration. However, the above-described maladaptations may negatively impact the quality of restored vision. To investigate this question, we employed human post-mortem retinas and transgenic rd1_Opto-mGluR6 mice expressing the optogenetic construct Opto-mGluR6 in OBCs and carrying the retinal degeneration rd1 mutation. We found significant changes in delayed rectifier potassium channel expression in OBCs of degenerative retinas. In particular, we found an increase in Kv1.3 expression already in early stages of degeneration. Immunohistochemistry localized Kv1.3 channels specifically to OBC axons. In whole-cell patch-clamp experiments, OBCs in the degenerated murine retina were less responsive, which could be reversed by application of the specific Kv1.3 antagonist Psora-4. Notably, Kv1.3 block significantly increased the amplitude and kinetics of Opto-mGluR6-mediated light responses in OBCs of the blind retina and increased the signal-to-noise ratio of light-triggered responses in retinal ganglion cells. We propose that reduction in Kv1.3 activity in the degenerated retina, either by pharmacological block or by KCNA3 gene silencing, could improve the quality of restored vision.


  • Open Access

    Bipolar cell targeted optogenetic gene therapy restores parallel retinal signaling and high-level vision in the degenerated retina

    by Jakub Kralik, Michiel van Wyk, Nino Stocker, Sonja Kleinlogel

    Optogenetic gene therapies to restore vision are in clinical trials. Whilst current clinical approaches target the ganglion cells, the output neurons of the retina, new molecular tools enable efficient targeting of the first order retinal interneurons, the bipolar cells, with the potential to restore a higher quality of vision. Here we investigate retinal signaling and behavioral vision in blind mice treated with bipolar cell targeted optogenetic gene therapies. All tested tools, including medium-wave opsin, Opto-mGluR6, and two new melanopsin based chimeras restored visual acuity and contrast sensitivity. The best performing opsin was a melanopsin-mGluR6 chimera, which in some cases restored visual acuities and contrast sensitivities that match wild-type animals. Light responses from the ganglion cells were robust with diverse receptive-field types, inferring elaborate inner retinal signaling. Our results highlight the potential of bipolar cell targeted optogenetics to recover high-level vision in human patients with end-stage retinal degenerations.


  • Open Access

    Bipolar Cell Targeted Optogenetic Gene Therapy Restores Parallel Retinal Signaling And High-Level Vision In The Degenerated Retina

    by Jakub Kralik, Michiel van Wyk, Nino Stocker, Sonja Kleinlogel

    Optogenetic gene therapies to restore vision are in clinical trials. Whilst current clinical approaches target the ganglion cells, the output neurons of the retina, new molecular tools enable efficient targeting of the first order retinal interneurons, the bipolar cells, with the potential to restore a higher quality of vision. Here we investigate retinal signaling and behavioral vision in blind mice treated with bipolar cell targeted optogenetic gene therapies. All tested tools, including medium-wave opsin, Opto-mGluR6 and two new melanopsin based chimeras restored visual acuity and contrast sensitivity. The best performing opsin was a novel melanopsin-mGluR6 chimera, which in some cases restored visual acuities and contrast sensitivities that match wild-type animals. Light re- sponses from the ganglion cells were robust with diverse receptive-field types, inferring elaborate inner retinal signaling. Our results highlight the potential of bipolar cell targeted optogenetics to recover high-level vision in human patients with end-stage retinal degenerations.


  • Open Access

    Functional Availability of ON-Bipolar Cells in the Degenerated Retina: Timing and Longevity of an Optogenetic Gene Therapy

    by Jakub Kralik, Sonja Kleinlogel

    Degenerative diseases of the retina are responsible for the death of photoreceptors and subsequent loss of vision in patients. Nevertheless, the inner retinal layers remain intact over an extended period of time, enabling the restoration of light sensitivity in blind retinas via the expression of optogenetic tools in the remaining retinal cells. The chimeric Opto-mGluR6 protein represents such a tool. With exclusive ON-bipolar cell expression, it combines the light-sensitive domains of melanopsin and the intracellular domains of the metabotropic glutamate receptor 6 (mGluR6), which naturally mediates light responses in these cells. Albeit vision restoration in blind mice by Opto-mGluR6 delivery was previously shown, much is left to be explored in regard to the effects of the timing of the treatment in the degenerated retina. We performed a functional evaluation of Opto-mGluR6-treated murine blind retinas using multi-electrode arrays (MEAs) and observed long-term functional preservation in the treated retinas, as well as successful therapeutical intervention in later stages of degeneration. Moreover, the treatment decreased the inherent retinal hyperactivity of the degenerated retinas to levels undistinguishable from healthy controls. Finally, we observed for the first time micro electroretinograms (mERGs) in optogenetically treated animals, corroborating the origin of Opto-mGluR6 signalling at the level of mGluR6 of ON-bipolar cells.